A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa

Journal of Acquired Immune Deficiency Syndromes

Volumn 60, Issue 2, 2012, Pages 150-157

  Mosam, Anisa ^a   Shaik, Fahmida ^b   Uldrick, Thomas S ^b,c,h   Esterhuizen, Tonya ^d   Friedland, Gerald H ^e   Scadden, David T ^f   Aboobaker, Jamila ^a   Coovadia, Hoosen M ^g  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c Yale University ^*  (United States)

^d UNIVERSITY OF KWAZULU NATAL   (South Africa)

^e YALE UNIVERSITY   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^h NATIONAL CANCER INSTITUTE   (United States)

Author keywords

AIDS; Highly active antiretroviral therapy; HIV; Kaposi sarcoma; South Africa

Indexed keywords

BLEOMYCIN; DOXORUBICIN; ETOPOSIDE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; VINCRISTINE;

ADULT; ANASARCA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELLULITIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DYSPNEA; ENCEPHALITIS; FEMALE; FEVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS ASSOCIATED KAPOSI SARCOMA; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; HYPONATREMIA; ISCHEMIA; KAPOSI SARCOMA; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OVERALL SURVIVAL; PARESTHESIA; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOUTH AFRICA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUBERCULOSIS;

ADULT; ANTI-HIV AGENTS; ANTIGENS, NEOPLASM; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG THERAPY; FEMALE; HUMANS; LAMIVUDINE; MALE; NEVIRAPINE; SARCOMA, KAPOSI; SOUTH AFRICA; STAVUDINE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84862119923     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318251aedd     Document Type: Article

References (35)

1. Jacobson LP, Yamashita TE, Detels R, et al. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 1999;21(suppl 1):S34-S41. (Pubitemid 29357647)
2. Mosam A, Carrara H, Shaik F, et al. Increasing incidence of Kaposi's sarcoma in black South Africans in KwaZulu-Natal, South Africa (1983-2006). Int J STD AIDS. 2009;20:553-556.
3. Dedicoat M, Vaithilingum M, Newton R. Treatment of Kaposi's sarcoma in HIV-1 infected individuals with emphasis on resource poor settings. Cochrane Database Syst Rev. 2003;(3):CD003256.
4. Dupont C, Vasseur E, Beauchet A, et al. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l'immunodeficience humaine. AIDS. 2000;14:987-993. (Pubitemid 30336059)
5. Cattelan AM, Calabro ML, De Rossi A, et al. Long-term clinical outcome of AIDS-related Kaposi's sarcoma during highly active antiretroviral therapy. Int J Oncol. 2005;27:779-785.
6. Gill J, Bourboulia D, Wilkinson J, et al. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma-associated herpesvirus infection in patients with and without Kaposi sarcoma. J Acquir Immune Defic Syndr. 2002;31:384-390. (Pubitemid 35397090)
7. Martin-Carbonero L, Barrios A, Saballs P, et al. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS. 2004;18:1737-1740. (Pubitemid 39095795)
8. Cianfrocca M, Lee S, Von Roenn J, et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer. 2010;116:3969-3977.
9. Sikora K, Advani S, Koroltchouk V, et al. Essential drugs for cancer therapy: a World Health Organization consultation. Ann Oncol. 1999;10: 385-390. (Pubitemid 29236414)
10. Olweny CL, Borok M, Gudza I, et al. Treatment of AIDS-associated Kaposi's sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial. Int J Cancer. 2005;113:632-639. (Pubitemid 40038741)
11. Mosam A, Uldrick TS, Shaik F, et al. An evaluation of the early effects of a combination antiretroviral therapy programme on the management of AIDS-associated Kaposi's sarcoma in KwaZulu-Natal, South Africa. Int J STD AIDS. 2011;22:671-673.
12. Biggar RJ, Engels EA, Ly S, et al. Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr. 2005;39:293-299. (Pubitemid 40923208)
13. Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. 1989;7:1201-1207. (Pubitemid 19220121)
14. Krown SE, Testa MA, Huang J. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. 1997;15: 3085-3092. (Pubitemid 27377500)
15. Gill PS, Rarick M, McCutchan JA, et al. Systemic treatment of AIDSrelated Kaposi's sarcoma: results of a randomized trial. Am J Med. 1991; 90:427-433.
16. Evans SR, Krown SE, Testa MA, et al. Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study. J Clin Oncol. 2002;20:3236-3241. (Pubitemid 34831520)
17. Mannheimer S, Friedland G, Matts J, et al. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002; 34:1115-1121. (Pubitemid 34289685)
18. Mannheimer S, Thackeray L, Huppler Hullsiek K, et al. A randomized comparison of two instruments for measuring self-reported antiretroviral adherence. AIDS Care. 2008;20(2):161-169. (Pubitemid 351651267)
19. Aaronson NK. Assessment of quality of life and benefits from adjuvant therapies in breast cancer. Recent Results Cancer Res. 1993;127: 201-210.
20. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376. (Pubitemid 23073154)
21. Martin-Carbonero L, Palacios R, Valencia E, et al. Long-term prognosisof HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin. Clin Infect Dis. 2008;47:410-417. (Pubitemid 352009365)
22. Lodi S, Guiguet M, Costagliola D, et al. Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. J Natl Cancer Inst. 2010;102:784-792.
23. Letang E, Almeida JM, Miro JM, et al. Predictors of immune reconstitution inflammatory syndrome-associated with Kaposi sarcoma in mozambique: a prospective study. J Acquir Immune Defic Syndr. 2010;53:589-597.
24. Uldrick TS, Wang V, O'Mahony D, et al. An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease. Clin Infect Dis. 2010;51:350-358.
25. Mosam A, Hurkchand HP, Cassol E, et al. Characteristics of HIV-1-associated Kaposi's sarcoma among women and men in South Africa. Int J STD AIDS. 2008;19:400-405.
26. Nasti G, Serraino D, Ridolfo A, et al. AIDS-associated Kaposi's sarcoma is more aggressive in women: a study of 54 patients. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:337-341. (Pubitemid 29143027)
27. Meditz AL, Borok M, MaWhinney S, et al. Gender differences in AIDSassociated Kaposi sarcoma in Harare, Zimbabwe. J Acquir Immune Defic Syndr. 2007;44:306-308. (Pubitemid 46328347)
28. Martinez V, Caumes E, Gambotti L, et al. Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy. Br J Cancer. 2006;94:1000-1006.
29. Bihl F, Mosam A, Henry LN, et al. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma. AIDS. 2007;21:1245-1252. (Pubitemid 46883478)
30. Bower M, Weir J, Francis N, et al. The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma. AIDS. 2009;23:1701-1706.
31. Krown SE. Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. J Clin Oncol. 2004;22:399-402.
32. Nguyen HQ, Magaret AS, Kitahata MM, et al. Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response. AIDS. 2008;22:937-945. (Pubitemid 351652244)
33. Gantt S, Carlsson J, Ikoma M, et al. The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro. Antimicrob Agents Chemother. 2011;55:2696-2703.
34. Uldrick TS, Polizzotto MN, Aleman K, et al. High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. Blood. 2011;117:6977-6986.
35. Osoba D, Northfelt DW, Budd DW, et al. Effect of treatment on healthrelated quality of life in acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma: a randomized trial of pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine. Cancer Invest. 2001;19:573-580. (Pubitemid 32675210)